NANOBIOTIX |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.49 EUR | +0.73% |
|
+2.04% | -17.32% |
| 25/04 | Transcript : Nanobiotix S.A., Q4 2023 Earnings Call, Apr 25, 2024 | |
| 24/04 | Nanobiotix S.A. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Chart calendar Nanobiotix
a6da1be31a58.6x6v6dFjNWr1InIIfyinG5E-ykn2M-nJ_GvqVK2pNRU.rHb1mbMrTFOvYwVZLkHdeOYM_HyxVLmtyz3HMvKdQ3CYV-u-4xpGA7tJOw~ee920cf422fb8f84cdcca0d3795f17b5
Upcoming events on Nanobiotix
Past events on Nanobiotix
| 25/04/2024 05:30 pm | Q4 2023 Earnings Call |
| 25/04/2024 02:10 am | Q4 2023 Earnings Release |
| 13/03/2024 07:45 pm | Guggenheim Healthy Altitudes Summit |
| 13/03/2024 06:10 pm | Leerink Partners Global Biopharma Conference |
| 08/02/2024 01:30 am | Guggenheim Healthcare Talks Biotechnology Conference |
| 16/11/2023 01:30 pm | Jefferies London Healthcare Conference |
| 14/11/2023 06:30 pm | Q3 2023 Earnings Call |
| 14/11/2023 02:45 am | Q3 2023 Earnings Release |
| 23/10/2023 | European Society for Medical Oncology Congress - Abstract No:5222 |
| 23/10/2023 | European Society for Medical Oncology Congress - Poster No:1631P |
| 05/10/2023 05:30 pm | American Society for Radiation Oncology Meeting |
| 05/10/2023 12:30 am | Meeting of the American Society for Radiation Oncology - ABSTRACT #55260 |
| 27/09/2023 05:30 pm | Q2 2023 Earnings Call |
| 27/09/2023 01:45 am | Q2 2023 Earnings Release |
| 12/09/2023 01:30 am | H.C. Wainwright Global Investment Conference |
| 01/09/2023 05:30 pm | Extraordinary Shareholders Meeting |
| 10/07/2023 06:00 pm | Nanobiotix SA and Janssen Pharmaceutica NV Licensing Agreement Call |
| 27/06/2023 05:30 pm | Annual General Meeting |
| 18/05/2023 01:45 am | Q1 2023 Earnings Release |
| 25/04/2023 05:30 pm | Q4 2022 Earnings Call |
Annual results
| Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
|
Net sales Million EUR | Released Forecast Spread | 2,54 3,75 -32.24% | 2,51 2,19 14.86% | 2,65 16,7 -84.15% | 4,78 1,36 250.08% | 15,3 | 23,5 |
|
EBITDA Million EUR | Released Forecast Spread | -45,0 -43,3 -4.07% | -34,7 -41,5 16.41% | -51,0 -72,0 29.14% | 0,00 -50,7 - | -30,9 | -43,2 |
|
EBIT Million EUR | Released Forecast Spread | -46,8 -43,9 -6.62% | -36,4 -38,8 6.05% | -52,6 -73,4 28.32% | -46,7 -51,3 9.04% | -29,6 | -37,5 |
|
Earnings before Tax (EBT) Million EUR | Released Forecast Spread | -50,9 -44,6 -14.15% | -33,6 -44,1 23.85% | -47,0 -118 60.07% | -57,0 -50,4 -13.19% | -45,8 | -45,2 |
|
Net income Million EUR | Released Forecast Spread | -50,9 -45,9 -10.87% | -33,6 -38,5 12.84% | -47,0 -74,2 36.66% | -57,0 -49,7 -14.69% | -42,3 | -40,5 |
|
EPS EUR | Released Forecast Spread | -2,35 -2,11 -11.21% | -1,40 -1,28 -9.33% | -1,35 -1,47 8.23% | -1,64 -1,57 -4.39% | -0,86 | -0,76 |
| Announcement Date | 17/03/20 | 17/03/21 | 30/03/22 | 24/04/23 | - | - |
Quarterly results
| Fiscal Period | December | 2019 S1 | 2019 S2 | 2020 S1 | 2020 S2 | 2021 S1 | 2021 Q4 | 2022 S1 | 2022 S2 | 2023 S1 | 2023 S2 | 2024 S1 | 2024 S2 | 2025 S1 | 2025 S2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million EUR | Released Forecast Spread | 1,82 1,70 7.55% | 0,72 1,95 -63.18% | 1,45 2,00 -27.6% | 1,06 1,90 -44% | 1,32 0,90 46.56% | 1,33 1,20 10.75% | 3,45 1,33 159.56% | 3,29 2,25 46.4% | 12,2 | 19,8 | 15,6 | 16,0 | 21,7 | |
|
EBITDA Million EUR | Released Forecast Spread | -23,3 | -24,6 -25,9 4.92% | -24,2 | |||||||||||
|
EBIT Million EUR | Released Forecast Spread | -20,5 -18,6 -10.03% | -26,3 -20,1 -31.23% | -18,4 -24,2 24.03% | -18,0 -21,7 16.85% | -29,8 -19,1 -55.91% | -14,1 -46,0 69.33% | -25,9 -23,6 -9.65% | -20,8 -24,0 13.2% | -25,4 -23,9 -6.16% | -10,8 | ||||
|
Earnings before Tax (EBT) Million EUR | Released Forecast Spread | -23,9 -18,0 -32.89% | -27,0 -20,7 -30.71% | -20,6 -25,6 19.62% | -13,0 -23,3 44.19% | -30,4 -20,3 -49.84% | -8,29 -46,4 82.14% | -26,4 -24,6 -7.12% | -30,7 -24,0 -27.67% | -28,1 -25,6 -9.84% | -17,7 | ||||
|
Net income Million EUR | Released Forecast Spread | -23,9 -18,0 -32.89% | -27,0 -20,7 -30.73% | -20,6 -25,6 19.61% | -13,0 -23,3 44.16% | -30,4 -20,3 -49.85% | -8,29 -46,4 82.14% | -26,4 -24,6 -7.14% | -30,7 -24,0 -27.68% | -28,1 -25,6 -9.86% | -23,6 | -18,8 | -19,7 | ||
|
EPS EUR | Released Forecast Spread | -1,15 -0,90 -27.78% | -1,20 -0,94 -28.34% | -0,91 -1,10 17.27% | -0,49 -0,70 30% | -0,88 -0,60 -46.67% | -0,76 -0,70 -8.57% | -0,80 -0,72 -11.11% | -0,35 | -0,30 | -0,40 | -0,38 | -0,27 | ||
| Announcement Date | 04/09/19 | 17/03/20 | 04/09/20 | 17/03/21 | 08/09/21 | 30/03/22 | 28/09/22 | 24/04/23 | 26/09/23 | - | - | - | - | - |
| 01/05/2024 | DYNE THERAPEUTICS, INC.: Q1 2024 Earnings Release (Projected) |
| 01/05/2024 | PROTAGONIST THERAPEUTICS, INC.: Q1 2024 Earnings Release (Projected) |
| 01/05/2024 | EDITAS MEDICINE, INC.: Q1 2024 Earnings Release (Projected) |
| 01/05/2024 | AZENTA, INC.: Q2 2024 Earnings Release (Projected) |
| 01/05/2024 04:00 pm | UNITED THERAPEUTICS CORPORATION: Q1 2024 Earnings Release |
| 01/05/2024 04:00 pm | BIO-TECHNE CORPORATION: Q3 2024 Earnings Release |
| 01/05/2024 04:30 pm | ALKERMES PLC: Q1 2024 Earnings Release |
| 02/05/2024 | VIR BIOTECHNOLOGY, INC.: Q1 2024 Earnings Release |
| 02/05/2024 | CELLDEX THERAPEUTICS, INC.: Q1 2024 Earnings Release (Projected) |
| 02/05/2024 | MIRUM PHARMACEUTICALS, INC.: Q1 2024 Earnings Release (Projected) |
Past sector events for Nanobiotix
| Today | CRISPR THERAPEUTICS AG: Q1 2024 Earnings Release (Projected) |
| 30/04/2024 01:35 am | QIAGEN N.V.: Q1 2024 Earnings Release |
| 29/04/2024 | BEIJING SUN-NOVO PHARMACEUTICAL RESEARCH CO., LTD.: Q1 2024 Earnings Release (Projected) |
| 29/04/2024 | SINO BIOLOGICAL,INC.: Q1 2024 Earnings Release |
| 29/04/2024 | JOINN LABORATORIES(CHINA)CO.,LTD.: Q1 2024 Earnings Release |
| 29/04/2024 | MORPHOSYS AG: Q1 2024 Earnings Release |
| 27/04/2024 | GEMPHARMATECH CO., LTD.: Q1 2024 Earnings Release |
| 27/04/2024 | GEMPHARMATECH CO., LTD.: Q4 2023 Earnings Release |
| 26/04/2024 10:30 am | BB BIOTECH AG: Q1 2024 Earnings Release |
| 26/04/2024 | BIDE PHARMATECH CO., LTD.: Q4 2023 Earnings Release |
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- NANO Stock
- Calendar Nanobiotix
